Physician profile
Melissa Yoon
NPI 1932707130
$1,145.98
in general payments reported to CMS, 2019-2025
14 companies · $907 in 2025
The $907 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.33 · 2022: $61.25 · 2023: $21.81 · 2024: $125 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $346.78 | 2023-2025 | |
| Madrigal Pharmaceuticals | $334.61 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $92.58 | 2021-2022 | |
| Janssen Biotech, INC. | $52.38 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.95 | 2025 | Xifaxan |
| Qol Medical, LLC | $47.10 | 2025 | Sucraid |
| Lilly USA, LLC | $43.24 | 2025 | Omvoh |
| Pfizer INC. | $36.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.61 | 2025 | Eohilia |
| Ipsen Biopharmaceuticals, INC | $33.33 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $23.84 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $21.32 | 2025 | Vowst |
| Ardelyx, INC. | $18.40 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $13.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.